ES2722803T3 - Fármaco que contiene lectinas de muérdago recombinantes para el tratamiento del melanoma maligno - Google Patents
Fármaco que contiene lectinas de muérdago recombinantes para el tratamiento del melanoma maligno Download PDFInfo
- Publication number
- ES2722803T3 ES2722803T3 ES12720117T ES12720117T ES2722803T3 ES 2722803 T3 ES2722803 T3 ES 2722803T3 ES 12720117 T ES12720117 T ES 12720117T ES 12720117 T ES12720117 T ES 12720117T ES 2722803 T3 ES2722803 T3 ES 2722803T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- drug containing
- containing recombinant
- malignant melanoma
- recombinant mistletoe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000014066 European mistletoe Nutrition 0.000 title abstract 3
- 102000004856 Lectins Human genes 0.000 title abstract 3
- 108090001090 Lectins Proteins 0.000 title abstract 3
- 235000012300 Rhipsalis cassutha Nutrition 0.000 title abstract 3
- 241000221012 Viscum Species 0.000 title abstract 3
- 239000002523 lectin Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 title 1
- 201000001441 melanoma Diseases 0.000 title 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Fármaco que contiene lectina de muérdago recombinante para su uso en el tratamiento de cáncer de piel en el ser humano, en donde la lectina de muérdago recombinante se compone de las secuencias de aminoácidos SEQ ID NO. 1 y SEQ ID NO. 4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11161400A EP2508195A1 (de) | 2011-04-06 | 2011-04-06 | Arzneimittel enthaltend rekombinante Mistellektine zur Behandlung des malignen Melanoms |
| PCT/EP2012/056479 WO2012136857A1 (de) | 2011-04-06 | 2012-04-10 | Arzneimittel enthaltend rekombinante mistellektine zur behandlung des malignen melanoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2722803T3 true ES2722803T3 (es) | 2019-08-16 |
Family
ID=44393740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12720117T Active ES2722803T3 (es) | 2011-04-06 | 2012-04-10 | Fármaco que contiene lectinas de muérdago recombinantes para el tratamiento del melanoma maligno |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20140080764A1 (es) |
| EP (2) | EP2508195A1 (es) |
| AU (1) | AU2012238523B2 (es) |
| CA (1) | CA2832376C (es) |
| DK (1) | DK2694090T3 (es) |
| ES (1) | ES2722803T3 (es) |
| PL (1) | PL2694090T3 (es) |
| RU (1) | RU2639445C2 (es) |
| TR (1) | TR201903484T4 (es) |
| UA (1) | UA115307C2 (es) |
| WO (1) | WO2012136857A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3205348A1 (de) * | 2016-02-15 | 2017-08-16 | Melema Pharma GmbH | Arzneimittel enthaltend rekombinante mistellektine zur behandlung von hirntumoren |
| JP2022539494A (ja) * | 2019-07-09 | 2022-09-12 | ユニケム ラボラトリーズ リミテッド | 組換えタンパク質の安定な製剤 |
| AU2021267196A1 (en) | 2020-05-07 | 2023-01-05 | Unichem Laboratories Ltd | Anti-cancer proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4221836A1 (de) * | 1992-07-03 | 1994-01-05 | Gabius Hans Joachim Prof Dr | Das biochemisch aufgereinigte Mistel-Lektin (ML-1) als therapeutisch anwendbarer Immunmodulator |
| EP0751221B1 (de) * | 1995-06-26 | 1998-09-09 | MADAUS AG Köln | Rekombinantes Mistellektin (rML) |
| DE19752597A1 (de) * | 1997-11-27 | 1999-06-10 | Madaus Ag | Verwendung von Lektinzubereitungen bei der Bekämpfung von Harnblasenkarzinomen |
| DE19804210A1 (de) * | 1998-02-03 | 1999-08-12 | Biosyn Arzneimittel Gmbh | Rekombinante Mistellektine |
| EP1456663B1 (de) * | 2001-12-21 | 2007-05-09 | Viscum AG | Verfahren zur bestimmung der responsivität eines individuums für mistellektin |
-
2011
- 2011-04-06 EP EP11161400A patent/EP2508195A1/de not_active Withdrawn
-
2012
- 2012-04-10 PL PL12720117T patent/PL2694090T3/pl unknown
- 2012-04-10 AU AU2012238523A patent/AU2012238523B2/en active Active
- 2012-04-10 TR TR2019/03484T patent/TR201903484T4/tr unknown
- 2012-04-10 US US14/009,961 patent/US20140080764A1/en not_active Abandoned
- 2012-04-10 CA CA2832376A patent/CA2832376C/en active Active
- 2012-04-10 DK DK12720117.6T patent/DK2694090T3/en active
- 2012-04-10 RU RU2013149175A patent/RU2639445C2/ru active
- 2012-04-10 WO PCT/EP2012/056479 patent/WO2012136857A1/de active Application Filing
- 2012-04-10 ES ES12720117T patent/ES2722803T3/es active Active
- 2012-04-10 EP EP12720117.6A patent/EP2694090B1/de active Active
- 2012-10-04 UA UAA201312897A patent/UA115307C2/uk unknown
-
2016
- 2016-03-08 US US15/064,371 patent/US9981007B2/en active Active
-
2018
- 2018-04-26 US US15/963,905 patent/US20180243366A1/en not_active Abandoned
-
2021
- 2021-07-30 US US17/389,858 patent/US20210379143A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2832376A1 (en) | 2012-10-11 |
| US9981007B2 (en) | 2018-05-29 |
| UA115307C2 (uk) | 2017-10-25 |
| EP2694090B1 (de) | 2019-01-16 |
| US20180243366A1 (en) | 2018-08-30 |
| WO2012136857A1 (de) | 2012-10-11 |
| AU2012238523A1 (en) | 2013-10-24 |
| AU2012238523B2 (en) | 2017-05-25 |
| CA2832376C (en) | 2020-03-24 |
| RU2639445C2 (ru) | 2017-12-21 |
| EP2694090A1 (de) | 2014-02-12 |
| DK2694090T3 (en) | 2019-04-15 |
| EP2508195A1 (de) | 2012-10-10 |
| RU2013149175A (ru) | 2015-05-20 |
| US20210379143A1 (en) | 2021-12-09 |
| PL2694090T3 (pl) | 2019-08-30 |
| US20160175391A1 (en) | 2016-06-23 |
| US20140080764A1 (en) | 2014-03-20 |
| TR201903484T4 (tr) | 2019-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| ECSP18082207A (es) | Neoantígenos y métodos de su uso | |
| CY1126074T1 (el) | Περιοχες gla ως παραγοντες στοχευσης | |
| CL2017001819A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
| BR112015022625A2 (pt) | micromatrizes para entrega de agente terapêutico e métodos de uso | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| ES2691070T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
| CL2016001405A1 (es) | A peptide mixture | |
| ECSP14013224A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| CL2015003704A1 (es) | Péptidos y peptidomiméticos en usos de combinación y tratamientos para la subpoblacion de pacientes con cáncer | |
| CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| CL2012001405A1 (es) | Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer. | |
| UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
| BR112013031084A2 (pt) | meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas | |
| EA201491856A1 (ru) | Терапевтическое применение белков фактора роста фибробластов 21 | |
| RS53893B1 (en) | USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT | |
| CU24405B1 (es) | Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros | |
| GT201400050A (es) | Derivados de anilina, su preparación y su aplicación terapéutica | |
| MX2018000570A (es) | Nuevas isoformas de tripsina y su uso. | |
| CR20160133A (es) | Derivados de fenilalanina sustituidos | |
| CO7151543A2 (es) | Combinaciones terapéuticas y métodos para tratar el melanoma |